ASMB - CIK 0001426800
ASSEMBLY BIOSCIENCES, INC. trades as ASMB. In its fiscal 2025 annual report the company posted revenue of $72.30M, up 153.5% from the prior year and net income of -$6.12M. This page tracks ASSEMBLY BIOSCIENCES, INC. through 873 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -474.7% to -8.5% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-27 |
| SCHEDULE 13D/A | - | 2026-05-27 |
| Major company event | 8-K | 2026-05-26 |
| Prospectus supplement | 424B5 | 2026-05-26 |
| Prospectus supplement | 424B5 | 2026-05-22 |
| Major company event | 8-K | 2026-05-22 |
| SCHEDULE 13G | - | 2026-05-11 |
| Quarterly report | 10-Q | 2026-05-07 |
The largest companies sharing ASSEMBLY BIOSCIENCES, INC.'s SEC industry classification (pharmaceutical preparations).
ASSEMBLY BIOSCIENCES, INC. reported revenue of $72.30M for fiscal year 2025, an increase of 153.5% year over year.
In its latest fiscal year ASSEMBLY BIOSCIENCES, INC. reported a net loss of $6.12M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.